Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/02/2012CA2805245A1 Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
02/02/2012CA2805078A1 Imidazole derivatives
02/02/2012CA2805043A1 Hetero-bicyclic derivatives as hcv inhibitors
02/02/2012CA2804855A1 Pharmaceutical compositions containing pemetrexed having extended storage stability
02/02/2012CA2804847A1 Sirna targeting vegfa and methods for treatment in vivo
02/02/2012CA2804199A1 Compositions and methods for inhibition of the jak pathway
02/02/2012CA2803689A1 Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
02/02/2012CA2803387A1 Cyclic amine azaheterocyclic carboxamides
02/01/2012EP2412825A1 Leukemia stem cell markers
02/01/2012EP2412805A1 Gene involved in immortalization of human cancer cell and use thereof
02/01/2012EP2412744A2 Method for preparing branched functionalised polymers using branched polyol cores
02/01/2012EP2412724A1 Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
02/01/2012EP2412717A1 Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
02/01/2012EP2412716A1 Partial and full agonists of A1 adenosine receptors
02/01/2012EP2412714A1 Method for the industrial purification of biologically active phycotoxins
02/01/2012EP2412713A1 Pyrazole compound
02/01/2012EP2412711A1 Indazolepropionic acid amide compound
02/01/2012EP2412710A1 Fused piperidine compound and pharmaceutical agent comprising same
02/01/2012EP2412708A1 Substituted 3-hydroxy-4-pyridone derivative
02/01/2012EP2412707A2 3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
02/01/2012EP2412706A2 Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
02/01/2012EP2412705A1 Novel therapeutic agent for cognitive impairment
02/01/2012EP2412701A1 Novel amide derivative and skin whitening agent
02/01/2012EP2412700A1 Method for producing bicyclic gamma-amino acid derivative
02/01/2012EP2412697A1 Process for producing carboxylic acid compound
02/01/2012EP2412377A1 Burdock fruit extract containing arctigenin at high content and process for producing same
02/01/2012EP2412375A1 Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease
02/01/2012EP2412374A1 Pharmaceutical composition for enhancing adiponectin production and food useful therefor
02/01/2012EP2412373A1 Method for preparing acyclovir 2/3 hydrate
02/01/2012EP2412372A1 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases
02/01/2012EP2412371A1 Compositions comprising iron chelators (deferiprone/deferasirox) for use in the treatment of mucormycosis and other fungal diseases
02/01/2012EP2412370A1 Matrix-type sustained release preparation containing basic additive
02/01/2012EP2412369A1 Coated solid preparation
02/01/2012EP2412368A1 Method and composition for the treatment of scars
02/01/2012EP2412250A2 Food composition for prodromal dementia patients
02/01/2012EP2411529A2 N-linked glycan biosynthesis modulators
02/01/2012EP2411527A1 Method for increasing concentration of avenanthramides in oats
02/01/2012EP2411521A1 Compositions for stimulation of mammalian innate immune resistance to pathogens
02/01/2012EP2411519A1 Kanamycin antisense nucleic acid for the treatment of cancer
02/01/2012EP2411518A2 Rna interference mediated inhibition of the high affinity ige receptor alpha chain (fcerla) gene expression using short interfering nucleic acid (sina)
02/01/2012EP2411516A1 RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
02/01/2012EP2411515A1 Use of microrna-199b-5p in medical and diagnostic field
02/01/2012EP2411514A1 Mirna and its targets respectively the proteins made based on the targets as a prognostic, diagnostic biomarker and therapeutic agent for cancer
02/01/2012EP2411397A1 Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
02/01/2012EP2411396A2 Thienopyrimidinedione derivatives as trpa1 modulators
02/01/2012EP2411393A1 Fused pyrimidine-dione derivatives as trpa1 modulators
02/01/2012EP2411391A1 Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
02/01/2012EP2411388A2 Process for the production of fused, tricyclic sulfonamides
02/01/2012EP2411383A1 Derivatives of 3-alkoxy-4,5-diarylthiophene-2-carboxamide, preparation thereof, and therapeutic use thereof
02/01/2012EP2411382A1 Compounds as cannabinoid receptor ligands
02/01/2012EP2411381A1 Substituted spiro-amide compounds
02/01/2012EP2411379A1 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
02/01/2012EP2411376A1 Inhibitors of nf-kb
02/01/2012EP2411375A1 Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
02/01/2012EP2411371A1 Compounds as cannabinoid receptor ligands
02/01/2012EP2411370A1 Compounds as cannabinoid receptor ligands
02/01/2012EP2411369A1 Fluoroquinolone carboxylic acid molecular crystals
02/01/2012EP2411368A1 Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
02/01/2012EP2411367A1 Anticancer derivatives, preparation thereof, and therapeutic use thereof
02/01/2012EP2411366A1 Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
02/01/2012EP2411365A1 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
02/01/2012EP2411364A1 Anticancer compounds, preparation thereof, and therapeutic use thereof
02/01/2012EP2411363A1 Substituted piperidines as par-1 antagonists
02/01/2012EP2411361A1 1,1,1-trifluoro-2-hydroxypropyl compounds
02/01/2012EP2411360A1 Radiolabeled fluorine derivatives of methionine
02/01/2012EP2411352A2 Antiviral compounds and uses thereof
02/01/2012EP2411052A2 Carrier comprising a vitamin e derivative
02/01/2012EP2411043A1 Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
02/01/2012EP2411031A2 Methods and compositions for the treatment of cancer
02/01/2012EP2411029A1 Neuroprotective compositions and methods
02/01/2012EP2411027A1 Use of a probiotic to regulate body weight
02/01/2012EP2411020A2 Compositions and methods for treatment of hemorrhage
02/01/2012EP2411019A2 RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
02/01/2012EP2411018A2 RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
02/01/2012EP2411017A2 Parenteral pharmaceutical composition for use in gene therapy
02/01/2012EP2411016A1 Water soluble defructosylated pea extract, and use thereof as a prebiotic agent
02/01/2012EP2411015A1 5- , 14- -androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure
02/01/2012EP2411014A2 A medicinal steroids cream and a process to make it
02/01/2012EP2411013A1 Intraocular sustained release drug delivery systems and methods for treating ocular conditions
02/01/2012EP2411012A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
02/01/2012EP2411011A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
02/01/2012EP2411010A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
02/01/2012EP2411009A1 Therapeutic uses of quinazolinedione derivatives
02/01/2012EP2411008A1 Compositions comprising water with deuterium for the prevention or treatment of allergic diseases and a process for the preparation thereof
02/01/2012EP2411007A2 Modulating ires-mediated translation
02/01/2012EP2411006A2 Compositions and methods for treatment of renal disease
02/01/2012EP2411005A1 Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
02/01/2012EP2411004A1 Use of andrographolide compounds for treating inflammation and airway disorders
02/01/2012EP2411003A1 Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (copd)
02/01/2012EP2411002A1 Microalgal polysaccharide compositions
02/01/2012EP2411001A1 P2x3, receptor antagonists for treatment of pain
02/01/2012EP2410999A2 Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions
02/01/2012EP2410998A2 Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
02/01/2012EP2410994A1 Pharmaceutical composition containing levodopa, entacapone and carbidopa
02/01/2012EP2410992A1 Ascorbate-linked nanosystems for brain delivery
02/01/2012EP2410988A1 Pharmaceutical composition containing a drug and sirna
02/01/2012EP2410987A1 Methods of treatment using combination therapy
02/01/2012EP2410986A2 Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
02/01/2012EP2410984A2 Anti-influenza formulations and methods
02/01/2012EP2410859A1 Transdermal delivery
1 ... 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 ... 7860